Inovio Pharmaceuticals, Inc. (NasdaqCM: INO)
Health Care · Biotechnology · US
$0.99
-10.20% today · -55.3% 1Y
Inovio Pharmaceuticals, Inc. (NasdaqCM: INO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $114.25M and employs 112 people.
Over the last twelve months the share price has lost 55.3%, trading between 0.56 and 2.72.
Tweenvest scores Inovio Pharmaceuticals, Inc. across four factors: quality 34/100, value 73/100, growth 0/100. Its strongest factor is value.
INO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $114.25M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -1.03
- Dividend yield
- —
- Beta (5Y)
- 1.61
- 52-week high
- $2.72
- 52-week low
- $0.56
- Avg volume (3M)
- —
- Shares outstanding
- 103.40M
- Employees
- 112
- Next earnings
- —
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
- ISIN
- US45773H4092
- Founded
- 1983
- Listed since
- Dec 8, 1998
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| 4basebio PLCAIM: 4BB | $115.66M | £5.63 | 0.00% |
| PMV Pharmaceuticals, Inc.NasdaqGS: PMVP | $114.78M | $1.35 | -11.18% |
| Genelux CorporationNasdaqCM: GNLX | $114.72M | $2.49 | -2.73% |
| Unicycive Therapeutics, Inc.NasdaqCM: UNCY | $114.49M | $3.69 | -10.22% |
| Tonix Pharmaceuticals Holding Corp.NasdaqGS: TNXP | $113.88M | $6.40 | -3.61% |
| Hamlet BioPharma AB (publ)XSAT: HAMLET B | $113.40M | Skr6.08 | +1.50% |
| Insight Molecular Diagnostics Inc.NasdaqCM: IMDX | $110.28M | $3.01 | -10.68% |
| PDS Biotechnology CorporationNasdaqCM: PDSB | $110.16M | $1.58 | +3.95% |
Figures last refreshed Oct 11, 2026.